고처리량 스크리닝(HTS) 시장 규모는 2025년부터 2032년까지 예측 기간 동안 10.61%의 연평균 복합 성장률(CAGR)로 확대될 것으로 예상됩니다. 세계 고처리량 스크리닝(HTS) 시장은 만성질환 및 감염성 질환의 유병률 증가, 연구 협력 확대, 주요 기업들의 제품 개발로 인해 빠른 성장이 예상됩니다. 신약 개발의 기술 발전과 정밀의료에 대한 수요 증가는 시장 확대에 기여하는 주요 요인 중 일부입니다. 또한, 신약 개발을 가속화하기 위한 자금 조달 증가는 2025년부터 2032년까지 예측 기간 동안 고처리량 스크리닝(HTS) 시장의 플러스 성장에 기여하는 주요 요인으로 작용할 것으로 예상됩니다.
미국 질병예방통제센터(CDC)가 2024년 2월 발표한 자료에 따르면, 2024년 미국에서는 약 1억 2,900만 명이 심장병, 암, 당뇨병, 비만, 고혈압 등 적어도 한 가지 이상의 주요 만성질환을 앓고 있는 것으로 추산됩니다. 암은 전 세계 사람들에게 영향을 미치는 주요 만성질환입니다. 국제암연구소가 2020년 12월에 실시한 조사에 따르면, 2020년 전 세계적으로 1,930만 명의 새로운 암 환자가 보고된 것으로 추정됩니다.
세계보건기구(WHO)가 2022년에 인용한 자료에 따르면, 2020년 전 세계적으로 약 226만 건의 유방암, 221만 건의 폐암, 193만 건의 대장암, 141만 건의 전립선암, 109만 건의 위암이 보고된 바 있습니다. 화학요법, 면역체계를 조절하는 약물을 발견할 수 있는 가능성을 가지고 있습니다. 또한, 시너지 효과를 발휘하는 약물의 조합을 식별하고, 개별 종양의 특정 분자 특성에 맞는 맞춤 치료 계획을 세우는 데에도 도움이 됩니다.
HTS 분석은 병원체 복제, 병원성, 숙주 세포 상호작용에 관여하는 중요한 미생물 효소 및 경로를 표적으로 삼아 잠재적인 신약 개발 타겟 및 선도 화합물을 식별할 수 있기 때문입니다. 3억 5,400만 명에 달할 것으로 추정됩니다. 따라서 감염 사례 증가는 진단 수요를 더욱 증가시켜 시장 성장에 기여할 것입니다.
HTS 분석 및 장비의 광범위한 사용으로 인해 주요 기업 간의 연구 협력이 증가하면서 시장 성장을 가속하고 있습니다. 이러한 기업들은 혁신적인 스마트 분석법을 개발하여 새로운 신약 타겟과 세포 경로를 식별하기 위한 초기 신약개발을 제공합니다. 예를 들어, 2023년 5월 Axxam S.p.A.(Axxam S.p.A.)는 Promega Corporation과 함께 소형화 및 완전 자동화된 고처리량 스크리닝(HTS) 셋업에 맞게 조정된 무세포 및 세포 기반의 최첨단 발광 기반 분석법을 개발하기 위해 연구 개발을 시작한다고 발표했습니다. 개발한다고 발표했습니다.
신약 개발 프로세스의 급격한 변화로 인해, 기술 발전은 고처리량 스크리닝(HTS)에서 매우 중요한 역할을 하고 있습니다. 인공지능(AI)은 신약개발의 고처리량 스크리닝(HTS)에 혁명을 일으켜 의약품 개발 초기 단계의 효율성, 정확성, 예측 능력을 크게 향상시키고 있습니다. 이러한 시장 개척은 고처리량 스크리닝(HTS)에 대한 수요를 촉진하여 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다.
세계의 고처리량 스크리닝(HTS)(High Throughput Screening) 시장에 대해 조사했으며, 시장 개요와 함께 제품별, 기술별, 용도별, 최종사용자별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 전해드립니다.
High-Throughput Screening Market by Product (Instruments, Reagents and Kits, and Software), Technology (Cell-Based Assays, Ultra-High-Throughput Screening, Lab-On-A-Chip Technology, Label-Free High-Throughput Screening, and Next-Generation Sequencing (NGS), Application (In Vitro ADME Analysis, Drug Discovery & Development, Therapeutic Drug Monitoring, Lead Optimization, and Others), End-User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Government Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of chronic and infectious diseases, growing research collaborations, and product development by key players
The high-throughput screening market is estimated to grow at a CAGR of 10.61% during the forecast period from 2025 to 2032. The global high-throughput screening market is expected to grow a rapid pace due to the rising prevalence of chronic and infectious diseases, growing research collaborations, and product developments by key players. Increasing technological advancements in drug discovery and the growing demand of precision medicine are some of the key factors contributing to propel the market expansion. Additionally, the increasing funding to accelerate drug discovery is also a key factor responsible for contributing to the positive growth of the high-throughput screening market during the forecast period from 2025 to 2032.
High-Throughput Screening Market Dynamics:
According to the data provided by the Centers for Disease Control and Prevention (CDC) published in February 2024, an estimated 129 million people were suffering from at least 1 major chronic disease such as heart disease, cancer, diabetes, obesity, and hypertension in the United States as of 2024. Cancer is a major chronic disease affecting people around the world. As per the study conducted by the International Agency for Research on Cancer in December 2020, mentioned, an estimated 19.3 million new cancer cases were reported in 2020 across the globe.
According to data cited by the World Health Organization (WHO) in 2022, around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020 globally. HTS has the potential to uncover innovative targeted treatments, chemotherapy options, or immune system-regulating medications for various cancer types. Additionally, it aids in pinpointing combinations of drugs that work together synergistically, as well as crafting personalized treatment plans tailored to the unique molecular characteristics of individual tumors.
The rising cases of infectious diseases such as HIV, hepatitis, and others is another key driver for the high-throughput screening (HTS) market, as HTS assays can target essential microbial enzymes or pathways involved in pathogen replication, virulence, or host-cell interactions to identify potential drug targets and lead compounds. According to the World Health Organization (WHO) in 2022, it was estimated that around 354 million people were living with Hepatitis B or C infections in 2022 globally. Therefore, the increasing number of cases of infectious diseases will further increase the demand for diagnosis, thus contributing to market growth.
The rising research collaborations among key players are bolstering market growth due to the extensive use of HTS assays and instruments. These players are developing innovative smart assays to offer early-stage drug discovery to identify novel drug targets and cellular pathways. For instance, in May 2023, Axxam S.p.A., announced that it entered into a research collaboration with Promega Corporation, to develop cutting-edge luminescence-based assays, both cell-free and cell-based, tailored for miniaturized and fully automated high-throughput screening (HTS) setups.
In September 2023, SCIEX, a US-based mass spectrometry and capillary electrophoresis solutions entered into a research partnership with HighRes Biosolutions for precision detection and quantification of molecules in drug discovery.
In September 2022, Illumina, Inc., a US-based biotechnology company launched NovaSeq X and NovaSeq X Plus developed for genomic drug discovery. The NovaSeq X Plus has the capacity to produce over 20,000 whole genomes annually, which is 2.5 times faster than previous sequencers. This significant increase in throughput speeds up genomic exploration and medical understanding, leading to advancements in disease comprehension and potentially revolutionizing patient care.
Technological advancements play a pivotal role in high-throughput screening due to rapid transformation in the drug discovery process. Artificial Intelligence (AI) has revolutionized high throughput screening (HTS) in drug discovery, markedly enhancing efficiency, precision, and predictive capacities during the initial phases of drug development. Such developments in the market drive the demand for high-throughput screening, which promises a positive growth outlook for the market during the forecast period.
However, the high cost associated with the instrumentation and drug discovery process, and complexities in the assay development process, among others are some of the key constraints that may limit the growth of the high-throughput screening market.
High-Throughput Screening Market Segment Analysis:
High-Throughput Screening Market by Product (Instruments, Reagents and Kits, and Software), Technology (Cell-Based Assays, Ultra-High-Throughput Screening, Lab-On-A-Chip Technology, Label-Free High-Throughput Screening, and Next-Generation Sequencing (NGS), Application (In Vitro ADME Analysis, Drug Discovery & Development, Therapeutic Drug Monitoring, Lead Optimization, and Others), End-User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Government Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the technology segment, the cell-based assay category was estimated to generate the largest revenue share in the high-throughput screening market in 2024. This can be attributed to cell-based assays, which constitute over half of all high-throughput drug screenings, serving purposes such as target validation and assessing ADMET (absorption, distribution, metabolism, elimination, and toxicity) in the initial phases of drug discovery. Key players in the market are developing innovative screening workflow automation to develop effective cellular assays to enhance drug discovery. For instance, in February 2023, Agilent Technologies Inc., a US-based pharmaceutical and medical technology company launched the xCELLigence RTCA HT (real-time cell analysis high-throughput) platform seamlessly integrates with the BioTek BioSpa 8 Automated Incubator. The xCELLigence RTCA HT technology has played a pivotal role in enabling high-throughput, swift, and quantitative monitoring of cytopathic effect (CPE), serving as a valuable tool for evaluating neutralizing activity and potency.
In January 2024, BD, a US-based pharmaceutical and medical technology company announced its collaboration with Hamilton, a laboratory automation technology company to develop robotics-compatible reagent kits to facilitate greater standardization and minimize human error during large-scale single-cell multiomics experiments to reduce potential biases.
Further, cell-based assays are versatile tools utilized in biomedical research and drug discovery screening. They effectively measure cytotoxicity, biological activity, biochemical mechanisms, and off-target interactions, aiding in the efficient evaluation of compounds and their potential applications. Therefore, the extensive use of cell-based assays category in primary and secondary screening will contribute to the growth of the segment, thereby driving the growth of the overall high-throughput screening market during the forecast period.
North America is expected to dominate the overall High-Throughput Screening Market:
North America was estimated to account for the largest market share of the high-throughput screening market in 2024. This can be attributed to the rising number of patients suffering from chronic diseases such as cancer. The increasing government support and research funding and the presence of major players are some of the key driving factors contributing to the growth of the high-throughput screening market in North America.
One of the prominent factors supporting the growth of the North America high-throughput screening market is the extensive use of HTS assays in the identification and validation of tumor markers indicating cancer development. For instance, according to National Cancer Institute 2020, it was estimated that around 1,806,590 cancer cases were diagnosed in the year 2020 in the United States. Additionally, as per the same source, prostate, lung, and colorectal cancer accounted for 43% of the cancer cases in men, and breast, lung, and colorectal making up to 50% of cancer cases in women. This indicates the huge need for early drug development for disease treatment, therefore leading to the growth of high-throughput screening market in the region.
As per the data published by to US Government Accountability Office in May 2023, The National Institutes of Health (NIH), an agency within the Department of Health and Human Services (HHS), stands as the primary public funder of biomedical research and development (R&D). Between fiscal years 2017 and 2021, NIH allocated USD 97 billion for basic research, USD 28 billion for clinical trials and associated endeavors, and USD 9 billion for the training of biomedical professionals, as part of its commitment to advancing biomedical R&D. Therefore, the increasing government support for R&D which requires high-throughput screening techniques for drug development is promoting the growth of the market in the region.
The presence of key players and the development of advanced technologies to enhance the drug discovery process is one of the key factors contributing to the growth of the market in the region. These players are leveraging innovative technologies to accelerate drug research and clinical trials. In February 2022, Thermo Fisher Scientific Inc., announced its partnership with Medidata. In this collaboration, Thermo Fisher's PPD clinical research business partnered with Medidata Acorn AI, the advanced analytics insights division of Medidata, to create PPD TrueCast. The comprehensive enterprise application merged vast patient recruitment and site performance data with predictive models and advanced analytics. Such development by key players is expected to foster the growth of the high-throughput screening market in North America.
High-Throughput Screening Market Key Players:
Some of the key market players operating in the high-throughput screening market include Agilent Technologies, Inc., Axxam S.p.A., Danaher Corporation, Bio-Rad Laboratories, Inc., Merck & Co., Inc., PerkinElmer Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., Promega Corporation, Aurora Biomed Inc., Illumina, Inc., Oxford Nanopore Technologies plc, Corning Incorporated, F. Hoffmann-La Roche Ltd, Sygnature Discovery, BPS Bioscience, Inc., Revvity, Charles River Laboratories, Hamilton Company, UPM Biomedicals, and others.
Recent Developmental Activities in the High-Throughput Screening Market:
Key Takeaways from the High-Throughput Screening Market Report Study
Target audience who can be benefited from this High-Throughput Screening Market Report Study
Frequently Asked Questions for the High-Throughput Screening Market: